Overview
Alector Q2 collaboration revenue declines to $7.9 mln from $15.1 mln year-over-year
Net loss narrows to $30.5 mln from $38.7 mln in Q2 2024
Cash reserves of $307.3 mln expected to fund operations into H2 2027
Outlook
Alector expects 2025 collaboration revenue between $13 mln and $18 mln
Alector anticipates 2025 R&D expenses between $130 mln and $140 mln
Alector sees 2025 G&A expenses between $55 mln and $65 mln
Company has cash runway into the second half of 2027
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | $7.87 mln | ||
Q2 EPS | -$0.3 | ||
Q2 Net Income | -$30.52 mln | ||
Q2 Basic EPS | -$0.3 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Alector Inc is $3.75, about 61.9% above its August 6 closing price of $1.43
Press Release: ID:nGNX7cZ7xk
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)